GlassScriptPhysician profile
Manmeet S Padda
NPI 1710928601
$4,172.52
in general payments reported to CMS, 2019-2025
31 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $103 · 2021: $402 · 2022: $479 · 2023: $565 · 2024: $916 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,692 · Education: $19.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,692.33 |
| Education | $19.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,030.69 | 2019-2025 | |
| Janssen Biotech, INC. | $528.92 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $409.70 | 2020-2025 | Entyvio, Gattex |
| Daiichi Sankyo INC. | $216.10 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $193.46 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $172.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $164.77 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $158.13 | 2024-2025 | Vegzelma, Zymfentra |
| Genzyme Corporation | $133.51 | 2022-2025 | |
| Pfizer INC. | $132.26 | 2024 | |
| Medtronic, INC. | $116.52 | 2021-2022 | |
| Qol Medical, LLC | $110.99 | 2019-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $97.95 | 2022-2024 | Dificid, Recarbrio, Zerbaxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.25 | 2019-2024 | Trulance |
| Ipsen Biopharmaceuticals, INC | $91.01 | 2024-2025 | Iqirvo, Bylvay |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $68.42 | 2022-2024 | Rebyota |
| Endogastric Solutions, INC | $62.40 | 2019-2020 | |
| Lumendi LLC | $51.61 | 2019 | |
| Phathom Pharmaceuticals, INC. | $50.72 | 2025 | Voquezna |
| Ardelyx, INC. | $41.50 | 2024-2025 | Ibsrela |
| Braintree Laboratories, INC. | $36.48 | 2019-2023 | Sutab |
| Aimmune Therapeutics, INC. | $33.47 | 2025 | Zenpep, Vowst |
| Vivus LLC | $30.38 | 2024 | Qsymia |
| Ucb, INC. | $29.51 | 2019 | |
| Shionogi INC | $28.20 | 2019 | |
| Evoke Pharma, INC. | $19.93 | 2023 | Gimoti |
| Abbott Laboratories | $18.05 | 2019 | |
| Celgene Corporation | $17.70 | 2023 | Zeposia |
| Ethicon US, LLC | $17.59 | 2019 | |
| Laborie Medical Technologies Corp. | $14.00 | 2024 | Alphaone |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$38,317.73 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manmeet Padda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.